A Phase 3 interventional study of SABER-Bupivacaine (Part 1) and SABER-Bupivacaine (Part 2) in Post Operative Pain, sponsored by Durect. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-13.
Sponsored by Durect (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 6th largest by enrollment, is one of 25 that started in 2015, is one of 42 in phase 3, and was the 78th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 25 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 399 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
This study is registered under Durect, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Durect is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Bausch Health Companies Inc. has 7 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a research study of SABER® -Bupivacaine, an experimental medication designed to reduce pain for up to 3 days after surgery. Given once by the surgeon at the end of surgery, SABER® - Bupivacaine delivers a locally-acting pain reliever directly to the surgical wound.
The purpose of this study is to measure how well it works in reducing pain after laparoscopic cholecystectomy (surgery to remove the gall bladder) and to investigate the safety of SABER®-Bupivacaine (its side effects).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SABER-Bupivacaine and Saline Placebo
Drug: SABER-Bupivacaine (Part 1) · Drug: Saline Placebo
SABER-Bupivacaine and Bupivacaine HCl
Drug: SABER-Bupivacaine (Part 2) · Drug: Bupivacaine HCl
5 ml once at end of surgery
Also known as: POSIMIR® bupivacaine solution
5 ml once at end of surgery
Also known as: POSIMIR® bupivacaine solution
5 ml once at end of surgery
Also known as: placebo
0.5%, 15 ml, once at end of surgery
Pain Intensity on Movement From 0-48 Hours Post-Treatment
A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 13 planned time points from 0 to 48 hours post-treatment. The values reported are mean pain scores for each treatment group.
Time frame: Assessed from 0 to 48 hours post-dose, summary measure (see description) reported.
Pain Intensity Using the NPRS-11 With Movement
A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 17 planned time points from 0 to 72 hours post-treatment. The values reported are mean pain scores for each treatment group.
Time frame: Assessed from 0 to 72 hours post-dose, summary measure (see description) reported.
Total IV Morphine-equivalent Dose of Rescue Opioids
IV morphine-equivalent dose
Time frame: 0-72 hrs. post dose (after surgery)
Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score
Score of Integrated Analgesia (SIA) is a composite endpoint that integrates pain assessment scores with opioid use over various collections of timepoints by ranking the pain score and the opioid use separately across treatments. After the scores are computed the means are calculated across time points to provide a single overall treatment effect. The composite SIA score ranges from -200 to 200 with -200 being the best case and 200 the worst case.
Time frame: 0 to 72 hours
Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours
Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl
Time frame: From PACU Discharge to 72 Hours post-treatment
Time to First Opioid Rescue Medication Use After Discharge From the PACU
Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl
Time frame: From PACU Discharge to 72 Hours post-treatment
Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS)
mPADSS is a tool used to determine eligibility for discharge from the PACU after ambulatory surgery. It includes an assessment of parameters such as vital signs, activity level, nausea/vomiting, pain, and surgical bleeding. For this trial, evaluation of eligibility for PACU discharge by mPADSS has been slightly modified to provide a standardized means of assessing eligibility for PACU discharge across multiple investigative sites and also ensures that nonmedical complications, such as a missing ride home, do not interfere with evaluation of test drug effects.
Time frame: From admission to discharge from PACU (Approximately 0 to 12 hours)
The study was conducted at 22 sites in the US. First subject was randomized on 17 November 2015. Study completion date was on 16 Aug 2017.
| Milestone | SABER-Bupivacaine (Part 1) | Saline Placebo (Part 1) | SABER-Bupivacaine (Part 2) | Bupivacaine HCL (Part 2) |
|---|---|---|---|---|
| Started | 48 | 46 | 153 | 152 |
| Dosed | 46 | 46 | 148 | 148 |
| Completed | 46 | 46 | 148 | 144 |
| Not completed | 2 | 0 | 5 | 8 |
| Withdrew: Not dosed | 2 | 0 | 5 | 4 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 2 |
A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 13 planned time points from 0 to 48 hours post-treatment. The values reported are mean pain scores for each treatment group.
| score on a scale | Part 2/SABER-Bupivacaine | Part 2/Bupivacaine HCl |
|---|---|---|
| Pain Intensity on Movement From 0-48 Hours Post-Treatment | 5.55 ± 0.065 | 5.87 ± 0.059 |
A derived measure computed based on a patient-reported numerical pain rating scale assessing pain as a whole number from 0 (no pain) to 10 (worst pain imaginable) when the subject sits up from a supine position. This measure was evaluated by electronic diary at 17 planned time points from 0 to 72 hours post-treatment. The values reported are mean pain scores for each treatment group.
| score on a scale | Part 1 and Part 2: SABER-Bupivacaine | Part 2: Bupivacaine HCl |
|---|---|---|
| Pain Intensity Using the NPRS-11 With Movement | 4.94 ± 0.049 | 5.40 ± 0.052 |
IV morphine-equivalent dose
| IV morphine equivalent (mg) | Part 1 and Part 2: SABER-Bupivacaine | Part 2: Bupivacaine HCl |
|---|---|---|
| Total IV Morphine-equivalent Dose of Rescue Opioids | 21.4 ± 1.37 | 22.6 ± 1.58 |
Score of Integrated Analgesia (SIA) is a composite endpoint that integrates pain assessment scores with opioid use over various collections of timepoints by ranking the pain score and the opioid use separately across treatments. After the scores are computed the means are calculated across time points to provide a single overall treatment effect. The composite SIA score ranges from -200 to 200 with -200 being the best case and 200 the worst case.
| score on a scale | Part 1 and Part 2: SABER-Bupivacaine | Part 2: Bupivacaine HCl |
|---|---|---|
| Composite Endpoint of Silverman's Integrated Analgesic (SIA) Assessment Score | -17.3 ± 8.83 | -1.5 ± 9.33 |
Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl
| participants | Part 1 and Part 2: SABER-Bupivacaine | Part 2: Bupivacaine HCl |
|---|---|---|
| Subjects Not Taking Rescue Medication From PACU Discharge to 72 Hours | 57 | 42 |
Pooled SABER-Bupivacaine parts 1 + 2 vs. Bupivacaine HCl
| hours | Part 1 and Part 2: SABER-Bupivacaine | Part 2: Bupivacaine HCl |
|---|---|---|
| Time to First Opioid Rescue Medication Use After Discharge From the PACU | 5.5 (3.5 to 7.7) | 6.1 (3.3 to 9.0) |
mPADSS is a tool used to determine eligibility for discharge from the PACU after ambulatory surgery. It includes an assessment of parameters such as vital signs, activity level, nausea/vomiting, pain, and surgical bleeding. For this trial, evaluation of eligibility for PACU discharge by mPADSS has been slightly modified to provide a standardized means of assessing eligibility for PACU discharge across multiple investigative sites and also ensures that nonmedical complications, such as a missing ride home, do not interfere with evaluation of test drug effects.
| hours | Part 1 and Part 2: SABER-Bupivacaine | Part 2: Bupivacaine HCl |
|---|---|---|
| Time to PACU Discharge Eligibility as Assessed by Modified Post-Anesthesia Discharge Scoring System (mPADSS) | 1.8 (1.8 to 1.9) | 1.9 (1.8 to 2.0) |
Collected over Approximately 0-60 days after surgery (duration of time over which each participant was assessed).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SABER-Bupivacaine (Part 1) | 0/45 (0%) | 1/45 (2.2%) | 43/45 (95.6%) |
| Saline Placebo (Part 1) | 0/47 (0%) | 0/47 (0%) | 47/47 (100%) |
| SABER-Bupivacaine (Part 2) | 0/148 (0%) | 5/148 (3.4%) | 148/148 (100%) |
| Bupivacaine HCL (Part 2) | 0/148 (0%) | 3/148 (2%) | 146/148 (98.6%) |
| Event | SABER-Bupivacaine (Part 1) | Saline Placebo (Part 1) | SABER-Bupivacaine (Part 2) | Bupivacaine HCL (Part 2) |
|---|---|---|---|---|
| DizzinessNervous system disorders | 1/45 | 0/47 | 0/148 | 0/148 |
| Abdominal abscessInfections and infestations | 0/45 | 0/47 | 0/148 | 1/148 |
| Bile duct stoneHepatobiliary disorders | 0/45 | 0/47 | 1/148 | 0/148 |
| DehydrationMetabolism and nutrition disorders | 0/45 | 0/47 | 1/148 | 0/148 |
| GastritisGastrointestinal disorders | 0/45 | 0/47 | 0/148 | 1/148 |
| Hepatic enzyme increasedInvestigations | 0/45 | 0/47 | 1/148 | 0/148 |
| HypotensionVascular disorders | 0/45 | 0/47 | 1/148 | 0/148 |
| PancreatitisGastrointestinal disorders | 0/45 | 0/47 | 1/148 | 0/148 |
| Pancreatitis acuteGastrointestinal disorders | 0/45 | 0/47 | 0/148 | 1/148 |
| Post procedural bile leakInjury, poisoning and procedural complications | 0/45 | 0/47 | 1/148 | 0/148 |
| Event | SABER-Bupivacaine (Part 1) | Saline Placebo (Part 1) | SABER-Bupivacaine (Part 2) | Bupivacaine HCL (Part 2) |
|---|---|---|---|---|
| Post procedural contusionInjury, poisoning and procedural complications | 41/45 | 33/47 | 142/148 | 110/148 |
| Somnolence (Solicited)Nervous system disorders | 24/45 | 22/47 | 73/148 | 65/148 |
| Procedural painInjury, poisoning and procedural complications | 19/45 | 21/47 | 32/148 | 35/148 |
| Constipation (Solicited)Gastrointestinal disorders | 20/45 | 19/47 | 65/148 | 58/148 |
| Headache (Solicited)Nervous system disorders | 17/45 | 15/47 | 53/148 | 49/148 |
| NauseaNervous system disorders | 8/45 | 11/47 | 47/148 | 51/148 |
| Nausea (solicited)Nervous system disorders | 10/45 | 15/47 | 42/148 | 45/148 |
| Dizziness (Solicited)Nervous system disorders | 11/45 | 9/47 | 38/148 | 40/148 |
| Pruritus (Solicited)Skin and subcutaneous tissue disorders | 5/45 | 11/47 | 31/148 | 27/148 |
| Dysgeusia (Solicited)Gastrointestinal disorders | 4/45 | 2/47 | 31/148 | 24/148 |
All Enrolled Subjects (ITT population)
| Age, Continuous(years) | SABER-Bupivacaine (Part 1) | Saline Placebo (Part 1) | SABER-Bupivacaine (Part 2) | Bupivacaine HCL (Part 2) | Total |
|---|---|---|---|---|---|
| Mean | 46.0 ± 14.2 | 41.8 ± 12.8 | 45.5 ± 13.5 | 44.7 ± 13.9 | 44.8 ± 13.67 |
| Sex: Female, Male(Participants) | SABER-Bupivacaine (Part 1) | Saline Placebo (Part 1) | SABER-Bupivacaine (Part 2) | Bupivacaine HCL (Part 2) | Total |
|---|---|---|---|---|---|
| Female | 31 | 29 | 115 | 117 | 292 |
| Male | 17 | 17 | 38 | 35 | 107 |
| Race (NIH/OMB)(Participants) | SABER-Bupivacaine (Part 1) | Saline Placebo (Part 1) | SABER-Bupivacaine (Part 2) | Bupivacaine HCL (Part 2) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 5 | 6 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 4 | 6 | 9 | 26 |
| White | 39 | 40 | 141 | 135 | 355 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 2 | 3 |
| Region of Enrollment(participants) | SABER-Bupivacaine (Part 1) | Saline Placebo (Part 1) | SABER-Bupivacaine (Part 2) | Bupivacaine HCL (Part 2) | Total |
|---|---|---|---|---|---|
| United States | 48 | 46 | 153 | 152 | 399 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Jun 2017, 19 months.
Results were first posted in Jul 2021, 4 years 1 month after primary completion. A results delay was requested in May 2018.
Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 19 months is above that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine